Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of ADtreatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007....
000 years. It has been used to treat arthritis, cough, liver disorders, poor eyesight, dermatitis and asthma. Now, some people believe that saffron is a brain-boosting agent and can enhance memory.